| dbo:abstract |
Sebelipase alfa, sold under the brand name Kanuma, is a recombinant form of the enzyme lysosomal acid lipase (LAL) that is used as a medication for the treatment of lysosomal acid lipase deficiency (LAL-D). It is administered via intraveneous infusion. It was approved for medical use in the European Union and in the United States in 2015. (en) Себелипаза альфа — рекомбинантная форма фермента . Получил статус орфанного препарата и одобрен для применения в США в 2015 году. Производится из белка яиц генетически модифицированных куриц. (ru) |
| dbo:alternativeName |
Kanuma (en) |
| dbo:drugbank |
DB11563 |
| dbo:kegg |
D10377 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/sebelipase%20alfa |
| dbo:wikiPageID |
48782942 (xsd:integer) |
| dbo:wikiPageLength |
6515 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1117052026 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbc:Biopharmaceuticals dbr:Chicken dbr:Genetic_recombination dbr:Orphan_drug dbr:Enzyme dbr:Genetic_engineering dbr:Alexion_Pharmaceuticals dbc:Orphan_drugs dbr:FDA dbr:Center_for_Drug_Evaluation_and_Research dbr:Center_for_Veterinary_Medicine dbc:AstraZeneca_brands dbc:Breakthrough_therapy dbr:Egg_white dbr:Medication dbr:Lysosomal_acid_lipase_deficiency dbr:Phases_of_clinical_research dbr:Synageva dbr:Lysosomal_acid_lipase |
| dbp:atcPrefix |
A16 (en) |
| dbp:atcSuffix |
AB14 (en) |
| dbp:chemspiderid |
none (en) |
| dbp:dailymedid |
Sebelipase_alfa (en) |
| dbp:drugbank |
DB11563 (en) |
| dbp:eliminationHalfLife |
360.0 |
| dbp:kegg |
D10377 (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalStatus |
Rx-only (en) |
| dbp:legalUk |
POM (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:licenceEu |
yes (en) |
| dbp:pregnancyAu |
B1 (en) |
| dbp:routesOfAdministration |
Intravenous infusion (en) |
| dbp:tradename |
Kanuma (en) |
| dbp:wikiPageUsesTemplate |
dbt:Gastrointestinal-drug-stub dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_dmy_dates dbt:Drugs.com dbt:AstraZeneca dbt:Other_alimentary_tract_and_metabolism_products |
| dcterms:subject |
dbc:Biopharmaceuticals dbc:Orphan_drugs dbc:AstraZeneca_brands dbc:Breakthrough_therapy |
| gold:hypernym |
dbr:Form |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Sebelipase alfa, sold under the brand name Kanuma, is a recombinant form of the enzyme lysosomal acid lipase (LAL) that is used as a medication for the treatment of lysosomal acid lipase deficiency (LAL-D). It is administered via intraveneous infusion. It was approved for medical use in the European Union and in the United States in 2015. (en) Себелипаза альфа — рекомбинантная форма фермента . Получил статус орфанного препарата и одобрен для применения в США в 2015 году. Производится из белка яиц генетически модифицированных куриц. (ru) |
| rdfs:label |
Sebelipase alfa (en) Sebelipase alfa (ru) |
| owl:sameAs |
yago-res:Sebelipase alfa wikidata:Sebelipase alfa dbpedia-fa:Sebelipase alfa dbpedia-ru:Sebelipase alfa https://global.dbpedia.org/id/24P5i |
| prov:wasDerivedFrom |
wikipedia-en:Sebelipase_alfa?oldid=1117052026&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Sebelipase_alfa |
| is dbo:wikiPageRedirects of |
dbr:Kanuma_(drug) dbr:Sebelipase_alpha |
| is dbo:wikiPageWikiLink of |
dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:Priority_review dbr:Kanuma_(drug) dbr:Alexion_Pharmaceuticals dbr:ATC_code_A16 dbr:Acid_lipase_disease dbr:Kanuma dbr:Lysosomal_acid_lipase_deficiency dbr:Synageva dbr:Sebelipase_alpha |
| is foaf:primaryTopic of |
wikipedia-en:Sebelipase_alfa |